CIK 0001583648
- Non-accelerated filer
- Smaller reporting company
PALVELLA THERAPEUTICS, INC.
Sign in to watch- Ticker
- PVLA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 300784346
- Phone
- +1 484-253-1461
- Business address
- 353 W. LANCASTER AVENUE, SUITE 200, WAYNE, PA, 19087
- Former names
- PIERIS PHARMACEUTICALS, INC., Marika Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,725,861
- in 7 filings, $11.7M under 10b5-1 plans
Net −$11,725,861. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 9 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-01-25 | Barbier Ann Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2019-01-25 | GERAGHTY JAMES A Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2018-10-25 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +3,829 | $2.86 | $11K | 3,829 |
| 2018-10-24 | Sherman Matthew L Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2018-10-24 | Kiener Peter A Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2018-09-14 | KIRITSY CHRISTOPHER P Director | Purchase | +5,000 | $5.11 | $26K | 10,000 |
| 2018-07-25 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +2,837 | $3.86 | $11K | 2,837 |
| 2018-05-15 | GERAGHTY JAMES A Director | Purchase | +10,000 | $5.75 | $58K | 20,000 |
| 2018-04-30 | ORBIMED ADVISORS LLC 10% owner | Sale | −989,600 | $6.35 | $6.3M | 4,511,130 |
| 2018-04-30 | ORBIMED ADVISORS LLC 10% owner | Sale | −10,400 | $6.35 | $66K | 38,870 |
| 2018-04-25 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +2,665 | $4.10 | $11K | 2,665 |
| 2018-04-25 | Barbier Ann Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2018-02-20 | Matis Louis Chief Development Officer | Grant or award · Stock Options (Right to buy) | +100,000 | 100,000 | ||
| 2018-02-20 | Reine Allan Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +53,833 | 53,833 | ||
| 2018-02-20 | Reine Allan Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +50,000 | 50,000 | ||
| 2018-02-20 | Yoder Stephen S. Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +325,000 | 325,000 | ||
| 2018-02-13 | ORBIMED ADVISORS LLC 10% owner | Option exercise | +6,057 | $4.68 | $28K | 5,506,787 |
| 2018-02-13 | ORBIMED ADVISORS LLC 10% owner | Option exercise | +58 | $4.68 | $271 | 49,328 |
| 2018-02-13 | ORBIMED ADVISORS LLC 10% owner | Option exercise | +1,765 | $5.08 | $9K | 5,508,552 |
| 2018-02-13 | ORBIMED ADVISORS LLC 10% owner | Option exercise | +17 | $5.08 | $86 | 49,345 |
Page 15 of 21 · 412 trades